

Fiona H Blackhall

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1780681/publications.pdf>

Version: 2024-02-01

264
papers

27,073
citations

13865

67
h-index

6300

158
g-index

268
all docs

268
docs citations

268
times ranked

29996
citing authors

#	ARTICLE	IF	CITATIONS
1	Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer. <i>New England Journal of Medicine</i> , 2013, 368, 2385-2394.	27.0	3,181
2	First-Line Crizotinib versus Chemotherapy in <i>ALK</i> -Positive Lung Cancer. <i>New England Journal of Medicine</i> , 2014, 371, 2167-2177.	27.0	2,808
3	Tracking the Evolution of Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2017, 376, 2109-2121.	27.0	1,786
4	Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. <i>Nature</i> , 2017, 545, 446-451.	27.8	1,287
5	Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. <i>Cell</i> , 2017, 171, 1259-1271.e11.	28.9	968
6	Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 1556-1563.	1.6	788
7	Clinical Significance and Molecular Characteristics of Circulating Tumor Cells and Circulating Tumor Microemboli in Patients With Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 525-532.	1.6	755
8	Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. <i>Nature Medicine</i> , 2014, 20, 897-903.	30.7	608
9	Molecular analysis of circulating tumour cells—biology and biomarkers. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 129-144.	27.6	535
10	Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. <i>Journal of Clinical Oncology</i> , 2017, 35, 1288-1296.	1.6	470
11	Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. <i>Lancet Oncology</i> , The, 2017, 18, 1116-1125.	10.7	415
12	Analysis of Circulating Tumor Cells in Patients with Non-small Cell Lung Cancer Using Epithelial Marker-Dependent and -Independent Approaches. <i>Journal of Thoracic Oncology</i> , 2012, 7, 306-315.	1.1	411
13	Circulating Tumor Cells as a Window on Metastasis Biology in Lung Cancer. <i>American Journal of Pathology</i> , 2011, 178, 989-996.	3.8	386
14	Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. <i>Immunity</i> , 2017, 46, 577-586.	14.3	323
15	Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in <i>ALK</i> -Mutation-Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2251-2258.	1.6	308
16	Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With <i>KRAS</i> -Mutant Advanced Non-Small Cell Lung Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1844.	7.4	281
17	Classification of Cough as a Symptom in Adults and Management Algorithms. <i>Chest</i> , 2018, 153, 196-209.	0.8	281
18	Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 1067-1074.	1.6	268

#	ARTICLE	IF	CITATIONS
19	Treatment of Unexplained Chronic Cough. <i>Chest</i> , 2016, 149, 27-44.	0.8	263
20	Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer. <i>Nature Medicine</i> , 2017, 23, 114-119.	30.7	260
21	Activity of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 926-937.	7.0	256
22	Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan-HER Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 3337-3344.	1.6	247
23	A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. <i>British Journal of Cancer</i> , 2012, 106, 508-516.	6.4	233
24	Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 4442-4451.	1.6	227
25	Anatomy and Neurophysiology of Cough. <i>Chest</i> , 2014, 146, 1633-1648.	0.8	227
26	Three-Gene Prognostic Classifier for Early-Stage Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 5562-5569.	1.6	226
27	Circulating tumour cells: their utility in cancer management and predicting outcomes. <i>Therapeutic Advances in Medical Oncology</i> , 2010, 2, 351-365.	3.2	224
28	Evaluation of Circulating Tumor Cells and Serological Cell Death Biomarkers in Small Cell Lung Cancer Patients Undergoing Chemotherapy. <i>American Journal of Pathology</i> , 2009, 175, 808-816.	3.8	223
29	Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014. <i>Journal of Clinical Oncology</i> , 2016, 34, 2858-2865.	1.6	216
30	K-ras Mutations in Non-Small-Cell Lung Carcinoma: A Review. <i>Clinical Lung Cancer</i> , 2006, 8, 30-38.	2.6	212
31	Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 1527-1533.	1.6	209
32	Vasculogenic mimicry in small cell lung cancer. <i>Nature Communications</i> , 2016, 7, 13322.	12.8	206
33	Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study. <i>PLoS Biology</i> , 2014, 12, e1001906.	5.6	185
34	International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer: MONET1. <i>Journal of Clinical Oncology</i> , 2012, 30, 2829-2836.	1.6	179
35	Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project. <i>Journal of Clinical Oncology</i> , 2014, 32, 2780-2787.	1.6	163
36	Chronic Cough Due to Gastroesophageal Reflux in Adults. <i>Chest</i> , 2016, 150, 1341-1360.	0.8	158

#	ARTICLE	IF	CITATIONS
37	Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?. <i>Journal of Thoracic Oncology</i> , 2016, 11, 453-474.	1.1	156
38	Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer. <i>Lung Cancer</i> , 2012, 76, 19-25.	2.0	153
39	Heparan sulfate proteoglycans and cancer. <i>British Journal of Cancer</i> , 2001, 85, 1094-1098.	6.4	152
40	Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse. <i>Nature Medicine</i> , 2019, 25, 1534-1539.	30.7	146
41	KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition. <i>EBioMedicine</i> , 2019, 41, 711-716.	6.1	142
42	Distribution and Clinical Significance of Heparan Sulfate Proteoglycans in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 5178-5186.	7.0	135
43	The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5153-5164.	7.0	126
44	Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer. <i>Oncologist</i> , 2020, 25, 55-63.	3.7	123
45	Is Serum or Plasma More Appropriate for Intersubject Comparisons in Metabolomic Studies? An Assessment in Patients with Small-Cell Lung Cancer. <i>Analytical Chemistry</i> , 2011, 83, 6689-6697.	6.5	119
46	Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy. <i>Annals of Oncology</i> , 2011, 22, 1507-1519.	1.2	117
47	Where next for gefitinib in patients with lung cancer?. <i>Lancet Oncology</i> , The, 2006, 7, 499-507.	10.7	116
48	Reliability and prognostic value of radiomic features are highly dependent on choice of feature extraction platform. <i>European Radiology</i> , 2020, 30, 6241-6250.	4.5	115
49	Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1547-1558.	1.1	108
50	Modafinil for the Treatment of Fatigue in Lung Cancer: Results of a Placebo-Controlled, Double-Blind, Randomized Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 1882-1888.	1.6	106
51	A biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity. <i>Nature Cancer</i> , 2020, 1, 437-451.	13.2	103
52	Tools for Assessing Outcomes in Studies of Chronic Cough. <i>Chest</i> , 2015, 147, 804-814.	0.8	99
53	Clinical evaluation of a novel microfluidic device for epitope-independent enrichment of circulating tumour cells in patients with small cell lung cancer. <i>Analyst</i> , The, 2016, 141, 669-678.	3.5	95
54	The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials. <i>Annals of Oncology</i> , 2010, 21, 2023-2028.	1.2	91

#	ARTICLE	IF	CITATIONS
55	Isolation and Extraction of Circulating Tumor DNA from Patients with Small Cell Lung Cancer. <i>Annals of the New York Academy of Sciences</i> , 2008, 1137, 98-107.	3.8	90
56	Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer. <i>Clinical Cancer Research</i> , 2003, 9, 2241-7.	7.0	90
57	Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer. <i>ESMO Open</i> , 2017, 2, e000219.	4.5	87
58	A qualitative exploration of a respiratory distress symptom cluster in lung cancer: Cough, breathlessness and fatigue. <i>Lung Cancer</i> , 2011, 71, 94-102.	2.0	86
59	Mechanisms of Resistance to KRASG12C Inhibitors. <i>Cancers</i> , 2021, 13, 151.	3.7	81
60	The strength of female sex as a prognostic factor in small-cell lung cancer: a pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical Research Council Clinical Trials Unit. <i>Annals of Oncology</i> , 2010, 21, 232-237.	1.2	80
61	Circulating Tumor Cells Detected in the Tumor-Draining Pulmonary Vein Are Associated with Disease Recurrence after Surgical Resection of NSCLC. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1793-1797.	1.1	80
62	Skp2 Gene Copy Number Aberrations Are Common in Non-Small Cell Lung Carcinoma, and Its Overexpression in Tumors with ras Mutation Is a Poor Prognostic Marker. <i>Clinical Cancer Research</i> , 2004, 10, 1984-1991.	7.0	79
63	Targeted agents in non-small cell lung cancer (NSCLC): Clinical developments and rationale for the combination with thoracic radiotherapy. <i>Cancer Treatment Reviews</i> , 2012, 38, 626-640.	7.7	76
64	Somatic Cough Syndrome (Previously Referred to as Psychogenic Cough) and Tic Cough (Previously) Tj ETQq0 0 0 rrgBT /Overlock 10 Tf 0.8	6.8	76
65	Semen cryopreservation, utilisation and reproductive outcome in men treated for Hodgkin's disease. <i>British Journal of Cancer</i> , 2002, 87, 381-384.	6.4	75
66	Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients with ALK-Positive Advanced Non-€Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1625-1633.	1.1	74
67	Genetic profiling of tumours using both circulating free DNA and circulating tumour cells isolated from the same preserved whole blood sample. <i>Molecular Oncology</i> , 2016, 10, 566-574.	4.6	74
68	Identification and Targeting of Long-Term Tumor-Propagating Cells in Small Cell Lung Cancer. <i>Cell Reports</i> , 2016, 16, 644-656.	6.4	73
69	Identification and functional analysis of SKA2 interaction with the glucocorticoid receptor. <i>Journal of Endocrinology</i> , 2008, 198, 499-509.	2.6	71
70	Guideline on the requirements of external quality assessment programs in molecular pathology. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013, 462, 27-37.	2.8	70
71	Management of the respiratory distress symptom cluster in lung cancer: a randomised controlled feasibility trial. <i>Supportive Care in Cancer</i> , 2015, 23, 3373-3384.	2.2	70
72	Optimisation of circulating biomarkers of cell death for routine clinical use. <i>Annals of Oncology</i> , 2008, 19, 990-995.	1.2	68

#	ARTICLE	IF	CITATIONS
73	Circulating tumor cells and CDX models as a tool for preclinical drug development. <i>Translational Lung Cancer Research</i> , 2017, 6, 397-408.	2.8	68
74	Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project. <i>Journal of Thoracic Oncology</i> , 2018, 13, 413-425.	1.1	66
75	Etiologies of Chronic Cough in Pediatric Cohorts. <i>Chest</i> , 2017, 152, 607-617.	0.8	63
76	Will liquid biopsies improve outcomes for patients with small-cell lung cancer?. <i>Lancet Oncology</i> , The, 2018, 19, e470-e481.	10.7	63
77	Managing Chronic Cough as a Symptom in Children and Management Algorithms. <i>Chest</i> , 2020, 158, 303-329.	0.8	63
78	A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma. <i>British Journal of Cancer</i> , 2001, 84, 465-469.	6.4	61
79	Interstitial Lung Disease in Lung Cancer. <i>Drug Safety</i> , 2005, 28, 103-113.	3.2	60
80	Pharmacologic and Nonpharmacologic Treatment for Acute Cough Associated With the Common Cold. <i>Chest</i> , 2017, 152, 1021-1037.	0.8	59
81	Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: A multi-institutional retrospective analysis. <i>Lung Cancer</i> , 2011, 72, 378-383.	2.0	56
82	Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer. <i>Annals of Oncology</i> , 2015, 26, 497-504.	1.2	56
83	Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET). <i>Journal of Clinical Oncology</i> , 2017, 35, 402-411.	1.6	54
84	Integrated molecular portrait of non-small cell lung cancers. <i>BMC Medical Genomics</i> , 2013, 6, 53.	1.5	51
85	Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue. <i>Cell Reports</i> , 2020, 31, 107550.	6.4	51
86	Symptomatic Treatment of Cough Among Adult Patients With Lung Cancer. <i>Chest</i> , 2017, 151, 861-874.	0.8	50
87	Treatment of Interstitial Lung Disease Associated Cough. <i>Chest</i> , 2018, 154, 904-917.	0.8	50
88	Variant Ciz1 is a circulating biomarker for early-stage lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E3128-35.	7.1	49
89	Profiling of Circulating Free DNA Using Targeted and Genome-wide Sequencing in Patients with SCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 216-230.	1.1	49
90	Final Efficacy and Safety Results of Pemetrexed Continuation Maintenance Therapy in the Elderly from the PARAMOUNT Phase III Study. <i>Journal of Thoracic Oncology</i> , 2014, 9, 991-997.	1.1	46

#	ARTICLE	IF	CITATIONS
91	Assessment of Intervention Fidelity and Recommendations for Researchers Conducting Studies on the Diagnosis and Treatment of Chronic Cough in the Adult. <i>Chest</i> , 2015, 148, 32-54.	0.8	46
92	Association of Chemoradiotherapy With Outcomes Among Patients With Stage I to II vs Stage III Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2019, 5, e185335.	7.1	46
93	Hypoxic human cancer cells are sensitized to BH-3 mimetic-induced apoptosis via downregulation of the Bcl-2 protein Mcl-1. <i>Journal of Clinical Investigation</i> , 2011, 121, 1075-1087.	8.2	46
94	The Rare YAP1 Subtype of SCLC Revisited in a Biobank of 39 Circulating Tumor Cell Patient Derived Explant Models: A Brief Report. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1836-1843.	1.1	45
95	X-linked inhibitor of apoptosis protein as a therapeutic target. <i>Expert Opinion on Therapeutic Targets</i> , 2007, 11, 1459-1471.	3.4	44
96	Novel therapeutic targets in lung cancer: Inhibitor of apoptosis proteins from laboratory to clinic. <i>Cancer Treatment Reviews</i> , 2007, 33, 203-212.	7.7	44
97	Clinical expert guidelines for the management of cough in lung cancer: report of a UK task group on cough. <i>Cough</i> , 2010, 6, 9.	2.7	44
98	Validating the prognostic value of marker genes derived from a non-small cell lung cancer microarray study. <i>Lung Cancer</i> , 2004, 46, 197-204.	2.0	43
99	Stability and Heterogeneity of Expression Profiles in Lung Cancer Specimens Harvested Following Surgical Resection. <i>Neoplasia</i> , 2004, 6, 761-767.	5.3	43
100	Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer. <i>British Journal of Cancer</i> , 2008, 99, 442-447.	6.4	43
101	Circulating Tumor Cells, Enumeration and Beyond. <i>Cancers</i> , 2010, 2, 1236-1250.	3.7	42
102	Review: Targeted therapies in small cell lung cancer: a review. <i>Therapeutic Advances in Medical Oncology</i> , 2010, 2, 25-37.	3.2	42
103	Considerations in Developing and Delivering a Nonpharmacological Intervention for Symptom Management in Lung Cancer: The Views of Patients and Informal Caregivers. <i>Journal of Pain and Symptom Management</i> , 2012, 44, 831-842.	1.2	41
104	Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing. <i>British Journal of Cancer</i> , 2014, 111, 413-420.	6.4	41
105	Radiotherapy for small-cell lung cancer—Where are we heading?. <i>Lung Cancer</i> , 2009, 63, 307-314.	2.0	40
106	A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project. <i>Lung Cancer</i> , 2019, 131, 95-103.	2.0	40
107	Binding of endostatin to endothelial heparan sulphate shows a differential requirement for specific sulphates. <i>Biochemical Journal</i> , 2003, 375, 131-139.	3.7	39
108	Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer—Evidence from a phase II trial. <i>Lung Cancer</i> , 2012, 76, 72-77.	2.0	39

#	ARTICLE	IF	CITATIONS
109	Biomarkers for small cell lung cancer: Neuroendocrine, epithelial and circulating tumour cells. <i>Lung Cancer</i> , 2012, 76, 263-268.	2.0	39
110	Early reduction in tumour [18F]fluorothymidine (FLT) uptake in patients with non-small cell lung cancer (NSCLC) treated with radiotherapy alone. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 682-693.	6.4	39
111	A local human V α 1 T cell population is associated with survival in nonsmall-cell lung cancer. <i>Nature Cancer</i> , 2022, 3, 696-709.	13.2	39
112	Protocol for the CONVERT trial—Concurrent ONce-daily VERSus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status. <i>BMJ Open</i> , 2016, 6, e009849.	1.9	37
113	Direct Ras G12C inhibitors: crossing the rubicon. <i>British Journal of Cancer</i> , 2019, 121, 197-198.	6.4	37
114	Compliance and Outcome of Elderly Patients Treated in the Concurrent Once-Daily Versus Twice-Daily Radiotherapy (CONVERT) Trial. <i>Journal of Thoracic Oncology</i> , 2019, 14, 63-71.	1.1	37
115	Targeting DNA damage in SCLC. <i>Lung Cancer</i> , 2017, 114, 12-22.	2.0	36
116	Using DNA sequencing data to quantify T cell fraction and therapy response. <i>Nature</i> , 2021, 597, 555-560.	27.8	36
117	Improving Survival and Reducing Toxicity with Chemotherapy in Advanced Non-Small Cell Lung Cancer. <i>Treatments in Respiratory Medicine</i> , 2005, 4, 71-84.	1.4	35
118	How can we optimise concurrent chemoradiotherapy for inoperable stage III non-small cell lung cancer?. <i>Lung Cancer</i> , 2014, 83, 117-125.	2.0	35
119	A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group. <i>Journal of Thoracic Disease</i> , 2018, 10, 3909-3921.	1.4	35
120	<i>UGT1A1*28</i> genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan. <i>Pharmacogenomics</i> , 2009, 10, 733-739.	1.3	34
121	A Phase I Study of Vandetanib in Combination with Vinorelbine/Cisplatin or Gemcitabine/Cisplatin as First-Line Treatment for Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1285-1288.	1.1	34
122	<i>Ex vivo</i> culture of cells derived from circulating tumour cell xenograft to support small cell lung cancer research and experimental therapeutics. <i>British Journal of Pharmacology</i> , 2019, 176, 436-450.	5.4	34
123	Cough in Patients With Lung Cancer. <i>Chest</i> , 2019, 155, 103-113.	0.8	34
124	Liquid Chromatography—Mass Spectrometry Calibration Transfer and Metabolomics Data Fusion. <i>Analytical Chemistry</i> , 2012, 84, 9848-9857.	6.5	33
125	Neuroendocrine and epithelial phenotypes in small-cell lung cancer: implications for metastasis and survival in patients. <i>British Journal of Cancer</i> , 2013, 108, 1704-1711.	6.4	32
126	Modeling of lung cancer by an orthotopically growing H460SM variant cell line reveals novel candidate genes for systemic metastasis. <i>Oncogene</i> , 2004, 23, 6316-6324.	5.9	31

#	ARTICLE	IF	CITATIONS
127	Lungscape: Resected Non-Small-Cell Lung Cancer Outcome by Clinical and Pathological Parameters. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1675-1684.	1.1	31
128	Assessment of Breathlessness in Lung Cancer: Psychometric Properties of the Dyspnea-12 Questionnaire. <i>Journal of Pain and Symptom Management</i> , 2017, 53, 208-215.	1.2	31
129	Treatment and detection of ALK-rearranged NSCLC. <i>Lung Cancer</i> , 2013, 81, 145-154.	2.0	30
130	Inhibition of PI3K/BMX Cell Survival Pathway Sensitizes to BH3 Mimetics in SCLC. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1248-1260.	4.1	30
131	Aprepitant for Cough in Lung Cancer. A Randomized Placebo-controlled Trial and Mechanistic Insights. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 737-745.	5.6	30
132	Evaluation of Antitumor Activity Using Change in Tumor Size of the Survivin Antisense Oligonucleotide LY2181308 in Combination with Docetaxel for Second-Line Treatment of Patients with Non-Small-Cell Lung Cancer: A Randomized Open-Label Phase II Study. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1704-1708.	1.1	29
133	Prognostic and predictive biomarkers in early stage NSCLC: CTCs and serum/plasma markers. <i>Translational Lung Cancer Research</i> , 2013, 2, 382-97.	2.8	29
134	The clinical utility of circulating tumour cells in patients with small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2017, 6, 409-417.	2.8	28
135	Small cell lung cancer and targeted therapies. <i>Current Opinion in Oncology</i> , 2007, 19, 103-108.	2.4	27
136	Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064). <i>European Journal of Cancer</i> , 2015, 51, 1511-1528.	2.8	27
137	DNA Methylation in Circulating Tumour DNA as a Biomarker for Cancer. <i>Biomarker Insights</i> , 2007, 2, 117727190700200.	2.5	26
138	Occupational and Environmental Contributions to Chronic Cough in Adults. <i>Chest</i> , 2016, 150, 894-907.	0.8	26
139	Applying Best-Worst scaling methodology to establish delivery preferences of a symptom supportive care intervention in patients with lung cancer. <i>Lung Cancer</i> , 2012, 77, 199-204.	2.0	25
140	Extrapulmonary small cell carcinoma: a clinicopathological study with identification of potential diagnostic mimics. <i>Histopathology</i> , 2012, 61, 454-464.	2.9	25
141	Cough in the Athlete. <i>Chest</i> , 2017, 151, 441-454.	0.8	25
142	Management of Unresectable Stage III Non-Small-Cell Lung Cancer with Combined-Modality Therapy: A Review of the Current Literature and Recommendations for Treatment. <i>Clinical Lung Cancer</i> , 2008, 9, 92-101.	2.6	24
143	Understanding cough and its management in lung cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2012, 6, 153-162.	1.3	24
144	Discovery and Validation of Predictive Biomarkers of Survival for Non-small Cell Lung Cancer Patients Undergoing Radical Radiotherapy: Two Proteins With Predictive Value. <i>EBioMedicine</i> , 2015, 2, 841-850.	6.1	24

#	ARTICLE	IF	CITATIONS
145	Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer. <i>British Journal of Cancer</i> , 2017, 117, 757-766.	6.4	24
146	Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. <i>Radiotherapy and Oncology</i> , 2019, 133, 163-166.	0.6	24
147	Selumetinib in the treatment of non-small-cell lung cancer. <i>Future Oncology</i> , 2016, 12, 2545-2560.	2.4	23
148	Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1588-1594.	1.1	21
149	Chemotherapy for advanced non-small cell lung cancer patients with performance status 2. <i>Current Opinion in Oncology</i> , 2005, 17, 135-139.	2.4	20
150	Gefitinib for the treatment of non-small-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1343-1357.	1.8	20
151	Considerations in developing and delivering a non-pharmacological intervention for symptom management in lung cancer: the views of health care professionals. <i>Supportive Care in Cancer</i> , 2012, 20, 2565-2574.	2.2	20
152	Clinical Utility of Circulating Tumour Cell Detection in Non-Small-Cell Lung Cancer. <i>Current Treatment Options in Oncology</i> , 2013, 14, 610-622.	3.0	20
153	Using Whole-Exome Sequencing to Identify Genetic Markers for Carboplatin and Gemcitabine-Induced Toxicities. <i>Clinical Cancer Research</i> , 2016, 22, 366-373.	7.0	20
154	Genetic alterations of lung adenocarcinoma in relation to smoking and ethnicity. <i>Lung Cancer</i> , 2003, 41, 91-99.	2.0	19
155	Optimization of Circulating Biomarkers of Obatoclox-Induced Cell Death in Patients with Small Cell Lung Cancer. <i>Neoplasia</i> , 2011, 13, 339-347.	5.3	19
156	Evaluation and validation of a robust single cell RNA-amplification protocol through transcriptional profiling of enriched lung cancer initiating cells. <i>BMC Genomics</i> , 2014, 15, 1129.	2.8	19
157	Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Squamous Non-Small-Cell Lung Cancer: Results From the Randomized Controlled MONET1 Study. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1154-1161.	1.1	19
158	The Manchester Cough in Lung Cancer Scale: The Development and Preliminary Validation of a New Assessment Tool. <i>Journal of Pain and Symptom Management</i> , 2013, 45, 179-190.	1.2	18
159	Development of a circulating miRNA assay to monitor tumor burden: From mouse to man. <i>Molecular Oncology</i> , 2016, 10, 282-291.	4.6	18
160	SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting. <i>British Journal of Cancer</i> , 2017, 117, 938-946.	6.4	18
161	Use of G-CSF during concurrent chemotherapy and thoracic radiotherapy in patients with limited-stage small-cell lung cancer safety data from a phase II trial. <i>Lung Cancer</i> , 2011, 74, 75-9.	2.0	17
162	A cross sectional study to determine the prevalence of cough and its impact in patients with lung cancer: a patient unmet need. <i>BMC Cancer</i> , 2020, 20, 9.	2.6	17

#	ARTICLE	IF	CITATIONS
163	Diagnostic Mutation Profiling and Validation of Non-Small-Cell Lung Cancer Small Biopsy Samples using a High Throughput Platform. <i>Journal of Thoracic Oncology</i> , 2015, 10, 784-792.	1.1	16
164	Cell Death, Inflammation, Tumor Burden, and Proliferation Blood Biomarkers Predict Lung Cancer Radiotherapy Response and Correlate With Tumor Volume and Proliferation Imaging. <i>Clinical Lung Cancer</i> , 2018, 19, 239-248.e7.	2.6	16
165	Angiogenesis inhibitors in the treatment of small cell and non-small cell lung cancer. <i>Hematology/Oncology Clinics of North America</i> , 2004, 18, 1121-1141.	2.2	15
166	Soluble guanylate cyclase signalling mediates etoposide resistance in progressing small cell lung cancer. <i>Nature Communications</i> , 2021, 12, 6652.	12.8	14
167	Management of NSCLC Disease Progression After First-Line EGFR Tyrosine Kinase Inhibitors: What Are the Issues and Potential Therapies?. <i>Drugs</i> , 2016, 76, 831-840.	10.9	13
168	TIAM1-RAC1 promote small-cell lung cancer cell survival through antagonizing Nur77-induced BCL2 conformational change. <i>Cell Reports</i> , 2021, 37, 109979.	6.4	13
169	Chemotherapy for advanced lung cancer. <i>European Journal of Cancer</i> , 2004, 40, 2345-2348.	2.8	12
170	The impact on the multidisciplinary team of molecular profiling for personalized therapy in non-small cell lung cancer. <i>Lung Cancer</i> , 2013, 79, 101-103.	2.0	12
171	Molecular analysis of single circulating tumour cells following long-term storage of clinical samples. <i>Molecular Oncology</i> , 2017, 11, 1687-1697.	4.6	12
172	Erlotinib in non-small cell lung cancer: a review. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 995-1002.	1.8	11
173	Gemcitabine and carboplatin in combination for the treatment of advanced, metastatic, non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 3265-3275.	1.8	11
174	Safety of G-CSF with concurrent chemo-radiotherapy in limited-stage small cell lung cancer - Secondary analysis of the randomised phase 3 CONVERT trial. <i>Lung Cancer</i> , 2021, 153, 165-170.	2.0	11
175	Targeting Blood Vessels for the Treatment of Non-Small Cell Lung Cancer. <i>Current Cancer Drug Targets</i> , 2008, 8, 392-403.	1.6	10
176	Is heterogeneity in stage 3 non-small cell lung cancer obscuring the potential benefits of dose-escalated concurrent chemo-radiotherapy in clinical trials?. <i>Lung Cancer</i> , 2018, 118, 139-147.	2.0	10
177	Developing and testing a web-based intervention to encourage early help-seeking in people with symptoms associated with lung cancer. <i>British Journal of Health Psychology</i> , 2019, 24, 31-65.	3.5	10
178	Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists. <i>British Journal of Cancer</i> , 2021, 125, 1210-1216.	6.4	10
179	Sequential Platinum-Based Chemotherapy-Thoracic Radiotherapy in Early Stage Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 5051s-5056s.	7.0	9
180	Management of cancer from an unknown primary. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 445-455.	1.8	9

#	ARTICLE	IF	CITATIONS
181	9084 POSTER A Global Phase 2 Study Including Efficacy, Safety and Patient-reported Outcomes (PROs) With Crizotinib in Patients (Pts) With ALK-positive Non-small Cell Lung Cancer (NSCLC). European Journal of Cancer, 2011, 47, S617.	2.8	9
182	Treatment of limited small cell lung cancer: an old or new challenge?. Current Opinion in Oncology, 2011, 23, 158-162.	2.4	9
183	Patient Experience of Symptoms and Side Effects when Treated with Osimertinib for Advanced Non-Small-Cell Lung Cancer: A Qualitative Interview Substudy. Patient, 2017, 10, 593-603.	2.7	9
184	Pharmacogenetics in the Management of Breast Cancer – Prospects for Individualised Treatment. Familial Cancer, 2006, 5, 151-157.	1.9	8
185	Improving Survival with Thoracic Radiotherapy in Patients with Small Cell Lung Cancer. The CONVERT and the REST Trials. Clinical Oncology, 2010, 22, 547-549.	1.4	8
186	EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells in small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 1653-1665.	2.8	8
187	Perspectives on novel therapies for bronchial carcinoma. Expert Opinion on Pharmacotherapy, 2005, 6, 1157-1167.	1.8	7
188	The Morphogenic Properties of Oligomeric Endostatin Are Dependent on Cell Surface Heparan Sulfate. Journal of Biological Chemistry, 2006, 281, 14813-14822.	3.4	7
189	Antivascular agents for non-small-cell lung cancer: current status and future directions. Expert Opinion on Investigational Drugs, 2009, 18, 1667-1686.	4.1	7
190	Individualised treatment in non-small cell lung cancer: precise tissue diagnosis for all?. Thorax, 2011, 66, 273-275.	5.6	7
191	Chronic Cough Related to Acute Viral Bronchiolitis in Children. Chest, 2018, 154, 378-382.	0.8	7
192	Investigation of myositis and scleroderma specific autoantibodies in patients with lung cancer. Arthritis Research and Therapy, 2018, 20, 176.	3.5	7
193	Brief report on the clinical characteristics of patients whose samples generate small cell lung cancer circulating tumour cell derived explants. Lung Cancer, 2020, 150, 216-220.	2.0	7
194	Current Status of Immunotherapy for Non-Small-Cell Lung Cancer. Tumori, 2016, 102, 337-351.	1.1	6
195	Cough in Ambulatory Immunocompromised Adults. Chest, 2017, 152, 1038-1042.	0.8	5
196	Global Physiology and Pathophysiology of Cough. Chest, 2021, 160, 1413-1423.	0.8	5
197	Radiotherapy in Extensive-disease Small Cell Lung Cancer. A Survey of Current UK Practice. Clinical Oncology, 2009, 21, 78.	1.4	4
198	Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group. Lung Cancer, 2011, 73, 338-344.	2.0	4

#	ARTICLE	IF	CITATIONS
199	103 Do treatment decisions made at lung cancer multi-disciplinary team meetings (MDTs) reflect the actual treatment given in practice?. Lung Cancer, 2013, 79, S36.	2.0	4
200	1: Circulating tumour cells from small cell lung cancer patients are tumourigenic. Lung Cancer, 2015, 87, S1.	2.0	4
201	Is it time to convert the frequency of radiotherapy in small-cell lung cancer? – Authors' reply. Lancet Oncology, The, 2017, 18, e556.	10.7	4
202	Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme. ESMO Open, 2018, 3, e000408.	4.5	4
203	Validation of ROS1 by immunohistochemistry against fluorescent in situ hybridisation on cytology and small biopsy samples in a large teaching hospital. Cytopathology, 2021, 32, 621-630.	0.7	4
204	Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay. NAR Cancer, 2022, 4, .	3.1	4
205	Real-World Data on Pembrolizumab for Pretreated Non-Small-Cell Lung Cancer: Clinical Outcome and Relevance of the Lung Immune Prognostic Index. Targeted Oncology, 2022, 17, 453-465.	3.6	4
206	EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients: how do we interpret the clinical and biomarker data?. Targeted Oncology, 2008, 3, 173-186.	3.6	3
207	Update on targeted therapies for small cell carcinoma of the lung. Targeted Oncology, 2008, 3, 205-215.	3.6	3
208	The Influence of Sex in Non-Small Cell Lung Cancer. Onkologie, 2009, 32, 547-548.	0.8	3
209	Availability of EGFR mutation status at first oncology consultation for advanced non-squamous non-small cell lung cancer patients. A pilot experience from the Christie. Lung Cancer, 2013, 82, 510-511.	2.0	3
210	First-Line Crizotinib Vs Pemetrexed + Cisplatin/Carboplatin in Asian Patients with Advanced Alk+ Nsclc in Profile 1014. Annals of Oncology, 2014, 25, v2.	1.2	3
211	Liquid Biopsy in Small Cell Lung Cancer – A Route to Improved Clinical Care?. Cells, 2020, 9, 2586.	4.1	3
212	Biology and clinical relevance of circulating tumour cells. Journal of Thoracic Disease, 2012, 4, 453-5.	1.4	3
213	B2-06: A pragmatic, randomised study to compare the hospitalisation rates of two platinum-based outpatient regimens (Gemcitabine/Cisplatin vs. Gemcitabine/Carboplatin) in non-small cell lung cancer (NSCLC) - UK Swiss collaboration. Journal of Thoracic Oncology, 2007, 2, S338.	1.1	2
214	100 The ‘‘CLIC’’ cough in lung cancer study: Co-morbidities are key predictors of cough. Lung Cancer, 2014, 83, S37.	2.0	2
215	Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer. Annals of Oncology, 2015, 26, ii15.	1.2	2
216	P2.03b-031 Impact of PD-L1 Status on Clinical Response in SELECT-1: Selumetinib + Docetaxel in KRASm Advanced NSCLC. Journal of Thoracic Oncology, 2017, 12, S952-S953.	1.1	2

#	ARTICLE	IF	CITATIONS
217	Molecular resistance mechanisms of ALK inhibitors and implications for therapeutic management of ALK-rearranged lung cancer patients. <i>Translational Cancer Research</i> , 2017, 6, S239-S245.	1.0	2
218	O-126 Expression profiling of matrix metalloproteinases (MMPs) and inhibitors reveals a novel prognostic role for MMP-19 in patients with non-small cell lung cancer. <i>Lung Cancer</i> , 2005, 49, S43-S44.	2.0	1
219	Dose-finding study of fixed dose gemcitabine and escalating doses of ifosfamide given on days 1 and 8 in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2006, 53, 165-170.	2.0	1
220	Prophylactic cranial irradiation (PCI) in extensive disease (ED) small cell lung cancer (SCLC): an audit of practice. <i>Lung Cancer</i> , 2008, 60, S4.	2.0	1
221	Omitting elective nodal irradiation (ENI) during thoracic irradiation in limited-stage small cell lung cancer (LS-SCLC) Patterns of failure from a phase II trial. <i>Lung Cancer</i> , 2010, 67, S10.	2.0	1
222	9072 POSTER Pemetrexed (Pern) Maintenance Therapy in Elderly Patients (Pts) With Good Performance Status (PS) – Analysis of PARAMOUNT Phase III Study of Pern Versus Placebo in Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC). <i>European Journal of Cancer</i> , 2011, 47, S613.	2.8	1
223	182 Do circulating tumour cell (CTC) counts correlate with tumour volume in limited disease small cell lung cancer (LD-SCLC)? An exploratory clinical study with survival outcomes. <i>Lung Cancer</i> , 2012, 75, S60.	2.0	1
224	P58 – The Characterisation and Subjective Assessment of Cough in Lung Cancer and Mesothelioma: The CLAIM Study. <i>Thorax</i> , 2013, 68, A101.1-A101.	5.6	1
225	Abstract 6238: Profiling of the circulating cell-free DNA methylome for detection and subtyping of small cell lung cancers. <i>Cancer Research</i> , 2022, 82, 6238-6238.	0.9	1
226	Platinum-based chemotherapy with thoracic radiotherapy in stage III good performance status non-small cell lung cancer patients. <i>European Journal of Cancer, Supplement</i> , 2005, 3, 41-50.	2.2	0
227	P-625 Quantitative PCR validation of putative non-small cell lungcancer (NSCLC) prognostic marker genes derived from multiple published microarray databases and reports. <i>Lung Cancer</i> , 2005, 49, S283.	2.0	0
228	427 POSTER Preclinical development of xiapuradamib therapy for lung cancer. <i>European Journal of Cancer, Supplement</i> , 2006, 4, 130.	2.2	0
229	35 CONVERT-A multicentre randomised controlled NCRN trial comparing accelerated twice-daily and high dose once-daily thoracic radiotherapy in good performance status (PS), limited small-cell lung cancer (LD SCLC) treated concurrently with cisplatin and etoposide. <i>Lung Cancer</i> , 2007, 57, S10.	2.0	0
230	Small Cell Lung Cancer (SCLC); any progress?. <i>European Journal of Cancer, Supplement</i> , 2007, 5, 398-399.	2.2	0
231	Tarceva in relapsed non-small cell lung cancer: experience from Northwest England. <i>Lung Cancer</i> , 2008, 60, S25-S26.	2.0	0
232	Feasibility and toxicity report from a phase II study of accelerated twice-daily (BDRT) versus high dose once-daily thoracic radiotherapy (ODRT) with concurrent chemotherapy for limited-stage small cell lung cancer (LS-SCLC). <i>Lung Cancer</i> , 2009, 63, S11-S12.	2.0	0
233	Detection of EGFR and KRAS mutations in circulating free DNA in patients with operable non small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2009, 63, S20.	2.0	0
234	Principles of Cancer Treatment. , 2010, , 1-9.		0

#	ARTICLE	IF	CITATIONS
235	Evaluating the safety of using G-CSF prophylaxis during concurrent thoracic chemo-radiotherapy (cTRT) in patients with limited-disease small-cell lung cancer (LD-SCLC): Evidence from a phase II trial. Lung Cancer, 2010, 67, S10-S11.	2.0	0
236	RADAR Radiation damage and resistance in patients with lung cancer. Lung Cancer, 2010, 67, S32-S33.	2.0	0
237	10IN NEW TOOLS IN THE MOLECULAR DIAGNOSTIC OF LUNG CANCER. Lung Cancer, 2011, 71, S7.	2.0	0
238	89 Management of stage III non-small-cell lung cancer (NSCLC) in the Greater Manchester and Cheshire Cancer Network (GMCCN): an analysis of current practice. Lung Cancer, 2012, 75, S30.	2.0	0
239	161 Acute toxicity of prophylactic cranial irradiation (PCI) in extensive stage small cell lung cancer (ES-SCLC): A prospective audit from a UK radiotherapy centre. Lung Cancer, 2012, 75, S53.	2.0	0
240	178 The National Lung Cancer Audit (NLCA) does not accurately record chemotherapy administration for patients with small cell lung cancer (SCLC) in the Greater Manchester and Cheshire Cancer Network (GMCCN). Lung Cancer, 2012, 75, S58-S59.	2.0	0
241	199 Pulmonary vein circulating tumour cells from patients undergoing curative resection of non-small cell lung cancer. Lung Cancer, 2012, 75, S65.	2.0	0
242	184 Toxicities and compliance to treatment in locally advanced non-small cell lung cancer (LA-NSCLC) treated with concurrent chemoradiotherapy (cTRT) at the Christie NHS Foundation Trust. Lung Cancer, 2013, 79, S63-S64.	2.0	0
243	48 Radical management of inoperable stage III non-small cell lung cancer (NSCLC) in the Greater Manchester and Cheshire Cancer Network (GMCCN) – an analysis of patient eligibility and justification for treatment. Lung Cancer, 2013, 79, S16.	2.0	0
244	P59 – The Characterisation of Cough in Lung Cancer. Thorax, 2013, 68, A101.2-A102.	5.6	0
245	264 Vasculogenic mimicry in small cell lung cancer. European Journal of Cancer, 2014, 50, 88.	2.8	0
246	31 The use of pemetrexed in advanced non-small cell lung cancer. Lung Cancer, 2014, 83, S12.	2.0	0
247	22 Mutation profiling of non-small cell lung cancer small biopsy samples using mass spectrometry and the SequenomLungCarta Panel. Lung Cancer, 2014, 83, S9.	2.0	0
248	59: CTCs and cfDNA, will they be useful for early detection of cancer?. European Journal of Cancer, 2014, 50, S15.	2.8	0
249	152 The impact of IMRT on the treatment of patients with N3M0 lung cancer at The Christie. Lung Cancer, 2014, 83, S56.	2.0	0
250	185 CONVERT – a successful international collaboration between the UK NCRI, Groupe Français de Pneumo-Cancérologie, Spanish Lung Cancer Group, EORTC and NCI Canada. Lung Cancer, 2014, 83, S69.	2.0	0
251	Outcomes of Octogenarian (>80 YO) Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): a Single Institution Experience from the Christie Hospital. Annals of Oncology, 2015, 26, i29.	1.2	0
252	113: Do standardised uptake values from PET-CT scans predict EGFR status of lung tumours?. Lung Cancer, 2015, 87, S41.	2.0	0

#	ARTICLE	IF	CITATIONS
253	144: A single centre's experience of toxicity, compliance and survival in patients with stage III locally advanced non-small cell lung cancer (LA-NSCLC) treated with concurrent chemo-radiotherapy (CCTRT). Lung Cancer, 2015, 87, S52-S53.	2.0	0
254	167: Thoracic radiotherapy in extensive stage small cell lung cancer. Lung Cancer, 2015, 87, S61.	2.0	0
255	Spotlight on circulating tumour cells. Translational Lung Cancer Research, 2017, 6, 396-396.	2.8	0
256	Abstract 2874: Understanding small cell lung cancer metastasis using circulating tumor cell (CTC)-derived tumor explant (CDX) models. , 2021, , .		0
257	E11-03: Controversy in small cell lung cancer: targeted therapy. Journal of Thoracic Oncology, 2007, 2, S251-S253.	1.1	0
258	Pharmacogenetics in Lung Cancer. , 2010, , 87-99.		0
259	Treatment of Limited-Stage Disease in Older Patients: The Role of Thoracic Radiotherapy and Prophylactic Cranial Irradiation. , 2013, , 223-232.		0
260	Abstract 1468: Circulating tumor cells (CTCs) and circulating tumor microemboli (CTM) from patients with small cell lung cancer (SCLC) show heterogeneity in epithelial to mesenchymal transition (EMT) phenotype and evidence of vasculogenic mimicry (VM).. , 2013, , .		0
261	Strategies in ALK Rearranged NSCLC Patients. , 2015, , 147-156.		0
262	Abstract 3060: Circulating tumor cells from small cell lung cancer patients are tumorigenic. , 2014, , .		0
263	Abstract IA05: Circulating tumor cells in lung cancer: Biomarkers, biology, and mouse models to study drug resistance. , 2015, , .		0
264	Abstract 2975: RAS precision medicine transatlantic partnership: Exploration of RAS and NF1 co-mutations in NSCLC. Cancer Research, 2022, 82, 2975-2975.	0.9	0